Nefopam for Analgesia Following Cardiac Surgery: A Randomized Placebo-Controlled Double-Blind Clinical Trial
Authors' conclusion
Nefopam was well tolerated and associated with statistically significant but clinically modest reductions in fentanyl use and pain scores after cardiac surgery
Study context
- Population
- Adults undergoing elective cardiac surgery via median sternotomy
- Participants
- 103 adults
- Comparison
- Nefopam vs placebo, with standardized IV fentanyl PCA in both groups
- Nefopamn = 50
- Placebon = 53reference
- Primary endpoint
- Cumulative fentanyl consumption
- Follow-up
- 48 hours
Methodological detailsdouble-blind, placebo-controlled, single tertiary care centre
- Double-blind
- Placebo-controlled
- Single tertiary care centre
Primary result
As reported in the abstract
P = 0.014
Secondary outcomes
| Outcome | P value |
|---|---|
| Pain score at rest (NRS 0-10) · 48 hoursLower with nefopam · overall pain remained mild | P = 0.03 |
| Pain score during movement (NRS 0-10) · 24 and 48 hoursNefopam vs Placebo · 24 hours; lower with nefopam | P = 0.04 |
| Pain score during movement (NRS 0-10) · 24 and 48 hoursNefopam vs Placebo · 48 hours; lower with nefopam | 0.01 |
Intubation duration, intensive care unit (ICU)/hospital LOS
- Did not differ between the 2 groups
Safety
Adverse events (eg, sinus tachycardia, agitation/delirium)
- Comparable in the 2 groups
Original publication
Nefopam for Analgesia Following Cardiac Surgery: A Randomized Placebo-Controlled Double-Blind Clinical Trial. J Cardiothorac Vasc Anesth. Published 23 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →